A Phase I Study of ZN-c3 and ZN-d5 in People with Recurrent or Persistent Acute Myeloid Leukemia


Full Title

A Phase 1/2 Dose Escalation Study of the BCL-2 Inhibitor ZN-d5 and the Wee1 Inhibitor ZN-c3 in Subjects with Acute Myeloid Leukemia


The purpose of this study is to find the highest dose of the investigational drug ZN-c3 that can be given alone or with the drug ZN-d5 in people with acute myeloid leukemia (AML) that came back or continued to grow despite prior treatment. ZN-c3 targets and blocks WEE1 kinase, a protein that plays an important role in helping cancer cells repair damaged DNA. ZN-d5 targets and inhibits the activity of BCL-2, a protein that contributes to cancer cell growth.

Participants in this study will receive ZN-c3 alone or with ZN-d5. Both medications are taken orally (by mouth).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have AML that came back or continued to grow despite treatment.
  • The serious side effects of previous therapies must go away before the study treatment is given.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.


For more information about this study and to ask about eligibility, please contact the office of Dr. Raajit Rampal at 646-608-3746.




Phase I/II (phases 1 and 2 combined)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID